

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Asymchem Laboratories (Tianjin) Co., Ltd.

凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

CLARIFICATION ANNOUNCEMENT IN RELATION TO FURTHER GRANTS UNDER THE H SHARE RESTRICTED SHARE SCHEME

Reference is made to the announcement of Asymchem Laboratories (Tianjin) Co., Ltd. (the “**Company**”) dated 8 July 2026 (the “**Announcement**”) in relation to further grants under the H Share Restricted Share Scheme. Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company would like to clarify on the following paragraph set out in both English and Chinese versions of the Announcement (with the changes bolded and underlined for easy reference):

The Board announces that on 8 July 2026, pursuant to the H Share Restricted Share Scheme, an aggregate of **640,000** Incentive Shares were granted to certain Employee Participants (the “**Grant**”).

Save as disclosed above, all other information disclosed in both English and Chinese versions of the Announcement remains unchanged.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
*Chairperson of the Board, Executive Director
and Chief Executive Officer*

Tianjin, PRC, 8 July 2026

As of the date of this announcement, the Board comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.